QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Huynh, M. Articles by Lau, D. H. Search for Related Content PubMed PubMed Citation Articles by Huynh, M. Articles by Lau, D. H.

Thrombotic Thrombocytopenic Purpura Associated with Quetiapine

Postdoctoral Fellow, University of California Davis Cancer Center, Sacramento, CA

Karen Chee, MD

Postdoctoral Fellow, University of California Davis Cancer Center

Derick HM Lau, MD PhD

Professor, University of California Davis Cancer Center and Northern California Veterans Affairs Health System, Sacramento

Reprints: Dr. Lau, University of California Davis Cancer Center, 4501 X St., Sacramento, CA 95817-2229, fax 916/734-7946, derick.lau{at}ucdmc.ucdavis.edu

OBJECTIVE: To report a case of thrombotic thrombocytopenic purpura (TTP) caused by the antipsychotic quetiapine on 2 occasions in the same patient and review the hematologic adverse events associated with quetiapine.

CASE SUMMARY: A 25-year-old African American male with a history of bipolar disorder was treated with quetiapine and developed thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure consistent with a diagnosis of TTP on 2 occasions 2 years apart. On each occasion, TTP was successfully treated with plasmapheresis.

DISCUSSION: Many medications, including antibiotics, immunosuppressants, and antineoplastics, have been implicated as causative agents of TTP. Although, as of this writing, a review of the medical literature reveals no previous report of TTP associated with quetiapine, the Food and Drug Administration database of the Adverse Event Reporting System has compiled, as of this writing, 3 cases of TTP occurring in patients on quetiapine as their sole medication. In addition, this database has recorded other common hematologic adverse effects, including neutropenia and thrombocytopenia, that are possibly associated with quetiapine. In our patient, quetiapine-associated TTP presented within a few days after exposure to the drug, with early thrombocytopenia followed by delayed appearance (2–3 days) of microangiopathic hemolysis.

CONCLUSIONS: An objective causality assessment suggests that quetiapine was the highly probable cause of TTP in this patient. Early recognition, discontinuation of the drug, and institution of plasmapheresis are paramount for prompt resolution of this life-threatening hematologic disorder.

Key Words: quetiapine, thrombotic thrombocytopenic purpura

Published Online, May 24, 2005. www.theannals.com, DOI 10.1345/aph.1G067